Vaxxinity, Inc. (VAXX): Price and Financial Metrics

Vaxxinity, Inc. (VAXX): $0.72

0.03 (+4.14%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add VAXX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#281 of 363

in industry

VAXX Price/Volume Stats

Current price $0.72 52-week high $3.10
Prev. close $0.69 52-week low $0.56
Day low $0.67 Volume 338,451
Day high $0.73 Avg. volume 411,807
50-day MA $0.71 Dividend yield N/A
200-day MA $1.36 Market Cap 90.94M

VAXX Stock Price Chart Interactive Chart >


Vaxxinity, Inc. (VAXX) Company Bio


Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD It is also developing UB-313 that targets Calcitonin Gene-Related Peptide to fight migraines; and Anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events, as well as UB-612/UB-612A for Covid-19 prevention. The company has a collaboration with United Biomedical, Inc. for the development of UB-612 in Taiwan. Vaxxinity, Inc. was founded in 2014 and is based in Dallas, Texas.


VAXX Latest News Stream


Event/Time News Detail
Loading, please wait...

VAXX Latest Social Stream


Loading social stream, please wait...

View Full VAXX Social Stream

Latest VAXX News From Around the Web

Below are the latest news stories about VAXXINITY INC that investors may wish to consider to help them evaluate VAXX as an investment opportunity.

The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity

Biogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog.

Yahoo | December 12, 2023

FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success

Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimer’s vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. government’s ClinicalTrials.gov database found. The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis.

Yahoo | November 20, 2023

Vaxxinity to Present at Upcoming November Medical and Investor Conferences

CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor conferences in November. Vaccines Summit – 2023Date: Tuesday, November 14, 2023 Time: 12:20 – 12:40 p.m. (ET)Title: UB-612: A novel peptide/protein subunit COVID-19 vaccine booster stimulated broadly neutralizi

Yahoo | November 13, 2023

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update. “We continue to advance our clinical programs and to validate our platform with the goal of addressing major chronic diseases with more convenient, cost-effective, and accessible immunotherapies worldwide. This quarter, we have

Yahoo | November 8, 2023

Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline

Key Insights The considerable ownership by private companies in Vaxxinity indicates that they collectively have a...

Yahoo | October 10, 2023

Read More 'VAXX' Stories Here

VAXX Price Returns

1-mo -7.07%
3-mo -15.29%
6-mo -47.45%
1-year -67.20%
3-year N/A
5-year N/A
YTD -15.29%
2023 -39.29%
2022 -75.04%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!